Age-related Macular Degeneration Treatment Market (By Product: Eylea, Lucentis, Beovu, Others; By Disease Type: Dry AMD, Wet AMD, By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global age-related macular degeneration treatment market size was USD 11.28 billion in 2023, calculated at USD 12.06 billion in 2024, and is expected to reach around USD 22.05 billion by 2033, expanding at a CAGR of 6.93% from 2024 to 2033. The rising developments in healthcare systems across the world is driving the growth of the age-related macular degeneration treatment market.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. age-related macular degeneration treatment market size was valued at USD 4.03 billion in 2023 and is predicted to be worth around USD 8.01 billion by 2033 with a CAGR of 7.11% from 2024 to 2033.
North America holds the largest market share in 2023 and is expected to maintain its dominance throughout the forecast period. The growth of this region is mainly driven by the rising technological developments in the healthcare industry. Also, the increasing cases of age-related macular degeneration (AMD) diseases in countries such as the U.S. and Canada have increased the demand for treatment of this eye disorder, thereby driving market growth. Moreover, the announcement of new government initiatives for developing treatment methodologies for age-related macular degeneration diseases has also boosted the growth of the age-related macular degeneration (AMD) treatment market. Furthermore, market players such as Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR LLC, Coherus, and others drive the growth of the age-related macular degeneration treatment market.
Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of this region is mainly driven by the scientific advancements in the healthcare sector in countries such as India, Israel, China, Japan, and some others. Also, the growing interest from the public and private sectors for development & research related to the treatment of age-related macular degeneration disease has also boosted the age-related macular degeneration treatment market growth. Additionally, the rising prevalence of age-related macular degeneration diseases (AMDs) across Asia increases the demand for treatment of this disease, which in turn drives the market growth. Moreover, rising government investment in countries such as India, China, and Japan to develop the eye care sector has boosted market growth. Furthermore, the presence of local market players in eye medications, such as Tarsier Pharma, Astellas Pharma, Chugai, and some others, has driven the growth of the age-related macular degeneration treatment market.
Market Overview
The age-related macular degeneration treatment market has grown rapidly with the advancements in modern science and technologies. Age-related macular degeneration occurs among patients due to several factors, such as unhealthy diet patterns and the growing adoption of a sedentary lifestyle. Also, excessive use of smartphones, tablets, televisions, and other electronic gadgets due to prolonged screen time leads to eye damage among people. The growing adoption of computers and laptops among working professionals is another factor that causes macular degeneration. Also, anti-VGEF injections are mainly administered to treat a macular degeneration patient above 50.
This industry is highly supported by a rise in eye clinics and ophthalmic centers worldwide. The governments of several countries have started collaborating with telehealth providers for the treatment of macular degeneration, which acts as a driving factor for industrial growth. This industry is also expected to grow. The integration of advanced eye testing systems in hospitals and ophthalmologic centers has also contributed to the market growth.
The developments and research of new medicines and therapies effective against macular degeneration will likely positively support age-related macular degeneration treatment market growth. The therapies and injections for treating this disorder can be purchased from hospital pharmacies, specialty pharmacies, and online platforms.
Report Coverage | Details |
Market Size in 2023 | USD 11.28 Billion |
Market Size in 2024 | USD 12.06 Billion |
Market Size by 2033 | USD 22.05 Billion |
Market Growth Rate | CAGR of 6.93% from 2024 to 2033 |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | Product, Disease Type, Distribution Channel, and Regions |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Rising cases of obesity across the world
The cases of obesity have increased rapidly in recent times due to factors such as diet, environmental factors, lack of exercise, and genetics. According to the World Obesity Atlas 2024, around 79% of adults will be suffering from overweight and obesity in low and middle-income countries in 2035. It is also estimated that the number of adults with obesity will increase from 0.81 billion in 2020 to 1.53 billion in 2035. Thus, with the growing cases of obesity, the associated macular degeneration problems also increase, increasing the demand for age-related macular degeneration treatment, thereby driving the age-related macular degeneration treatment market growth.
Availability of biosimilars and off-label drugs
The availability of several biosimilars that are found effective for the treatment of macular degeneration disorder has allowed people to take up these medicines due to their affordability. This, in turn, restrains the market growth to some extent. Moreover, easy accessibility of off-label drugs in local medical shops at lower prices is also expected to restrain the growth of the age-related macular degeneration treatment market during the forecast period.
Genetic therapies to shape the future of the market
There are several medications available in the market for the treatment of macular degeneration problems around the world. Recently, scientific advancements in genetic engineering have also enabled biotechnology companies to produce gene therapies for treating age-related macular degeneration disorders. Thus, growing developments in gene therapies for eye treatment are expected to create ample growth opportunities for the age-related macular degeneration treatment market players in the future.
The eyelea segment held the largest share in 2023, and it is expected to maintain its dominance throughout the forecast period. The growth of this segment is driven by the growing number of patients suffering from wet age-related macular degeneration (AMD) disease. Also, rising approval of aflibercept by various organizations for treating wet age-related macular degeneration (AMD) disorder has driven market growth.
The Beovu segment is expected to be the fastest-growing segment during the forecast period. The growth of this segment can be attributed to rising developments in the pharmaceutical sector. Also, the growing application of beloved for treating patients suffering from chronic eye disorders such as AMD and DME drives the growth of the wet age-related macular degeneration treatment market. The European Union recognized Beovu as the most effective medication for treating adults with eye problems.
The wet AMD segment held the largest market share in 2023. The growth of this segment is generally driven by a rising patient pool along with improved diagnosis and drug treatment for treating this disease. Also, the growing geriatric population coupled with rising developments in therapeutics for treating wet AMD has driven the growth of the age-related macular degeneration treatment market. Moreover, healthcare care companies are constantly engaged in research & development of wet AMD medications and adopting strategies such as approvals, product launches, and some others, which, in turn, drive market growth.
The dry AMD segment is expected to be the fastest-growing segment during the forecast period. The growth of this segment is mainly driven by the rising number of clinical trials for the treatment of dry AMD. Moreover, the development of high-grade anti-VGEFs for the treatment of dry AMD has driven the growth of the age-related macular degeneration treatment market. Also, the growing number of ophthalmic centers that are engaged in treating dry AMDs is boosting market growth.
The hospital pharmacy segment dominated the market in 2023 and is expected to continue its dominance during the forecast period. The growth of this segment is generally driven by the rise in the number of public hospitals across the world. Also, patients suffering from Dry AMD and Wet AMD have increased globally, which increases the demand for macular degeneration treatment in hospitals, thereby driving the market growth. Moreover, the availability of quality doctors in hospitals, along with the construction of hospitals with well-equipped pharmacies having huge stocks of medicines, has also driven the growth of the age-related macular degeneration treatment market.
The specialty pharmacy segment is estimated to grow with the highest CAGR during the forecast period. The growth of this segment is generally driven by the growing demand for macular degeneration treatment therapies among people across the world. Also, these pharmacies keep huge stocks of costly medications and allow insurance reimbursements for buying various medicines, thereby driving market growth. Moreover, specialty pharmacies provide home deliveries of medicines that further drive the growth of the age-related macular degeneration treatment market.
Recent Developments
Segments Covered in the Report
By Product
By Disease Type
By Distribution Channel
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Age-related Macular Degeneration Treatment Market
5.1. COVID-19 Landscape: Age-related Macular Degeneration Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Age-related Macular Degeneration Treatment Market, By Product
8.1. Age-related Macular Degeneration Treatment Market, by Product, 2024-2033
8.1.1 Eylea
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Lucentis
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Beovu
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Age-related Macular Degeneration Treatment Market, By Disease Type
9.1. Age-related Macular Degeneration Treatment Market, by Disease Type, 2024-2033
9.1.1. Dry AMD
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Wet AMD
9.1.2.1. Market Revenue and Forecast (2021-2033)
2021-2033)
Chapter 10. Global Age-related Macular Degeneration Treatment Market, By Distribution Channel
10.1. Age-related Macular Degeneration Treatment Market, by Distribution Channel, 2024-2033
10.1.1. Hospital Pharmacy
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Specialty Pharmacy
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Online Pharmacy
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Age-related Macular Degeneration Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Disease Type (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
Chapter 12. Company Profiles
12.1. F. Hoffmann-La Roche Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pfizer Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Bausch Health Companies Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Regeneron Pharmaceuticals Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Amgen Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Bayer AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Biogen
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Samsung Bioepis
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Abbvie, Inc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client